13 Oct 2022 17:55
CORRECT: Coral Products buys Ecodeck; Evgen Pharma recruits
(Correcting Harmony Energy Income Trust's use of funds.)
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
EVG.L Share News (EVG)
EVG Share
Price
EVG Share
News
EVG Share
Chat
EVG Share
Trades
EVG
Live RNS
EVG Share
Charts
EVG Broker
Ratings
EVG Directors
Deals
EVG Financial
Diary
EVG
Fundamentals
EVG Short
Positions
EVG
Media
EVG.L Information
- There is currently no data for EVG
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Evgen Pharma receives go ahead for haemorrhage drug trial
Wed, 11th Jan 2017 09:23
(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial of SFX-01 in subarachnoid haemorrhage (SAH).The DSMB review was part of the SAS trial protocol and was triggered by the 20th patient being does for a minimum of seven days whilst in hospital care. The review resulted in a recommendation to proceed as planned, continuing the dosages after being discharged for up to 28 days.SFX-01, a synthetic and stabilised version of the naturally occurring plant compound sulforaphane, potentially represents a new class of drug in SAH, with a mechanism of action that specifically targets the Nrf-2 pathway and has the effect of reducing the oxidative stress and toxicity caused by free haemoglobin from the haemorrhage.Nimodipine is the current standard of care and has a different action. It has been generic for more than 20 years during which time there have been no significant clinical advances in the treatment of SAH.The SAS trial is a randomised, double blind, placebo controlled study in which half of the patients will receive SFX-01 and nimodipine and the other half will receive placebo ad nimodipine. A total of 90 patients will be enrolled. A total of 26 patients have been enrolled in the study to date.Chief executive of Pharma Dr Stephen Franklin said: "We are delighted that the DSMB has given a favourable review of our Phase II study of SFX-01 in subarachnoid haemorrhage, a rare but devastating condition with high unmet clinical need. This is the first safety review of SFX-01 in a patient cohort and as such represents an important milestone in the clinical development of SFX-01."The share price fell 1.63% to 24.10p at 1027 GMT on Wednesday.
More News
12 Oct 2022 21:46
TRADING UPDATES: Coral Products buys Ecodeck; Evgen Pharma recruits
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more12 Oct 2022 12:23
Evgen starts recruiting volunteers for trial of lead asset
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the start of recruitment for the pharmacokinetic and pharmacodynamic trial in healthy volunteers, and the decision to commence an investigator-sponsored clinical study for the glioblastoma programme on Wednesday.
Read more10 Oct 2022 12:10
LONDON MARKET MIDDAY: FTSE 100 trims opening loss amid Fed hike worry
(Alliance News) - European equities traded off session lows heading into Monday afternoon, finding some poise after a poor open, as markets deal with the fallout from last week's US jobs report.
Read more10 Oct 2022 11:00
AIM WINNERS & LOSERS: Europa Oil, i3 Energy slide as well disappoints
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.
Read more10 Oct 2022 09:58
Evgen Pharma shares jump 65% as licences SFX-01 composition for autism
(Alliance News) - Evgen Pharma PLC on Monday said it has signed a licencing deal for up to USD160.5 million with Stalicla SA for the global rights to its lead asset SFX-01 in neurodevelopmental disorders and schizophrenia.
Read more14 Jul 2022 16:39
UK shareholder meetings calendar - next 7 days
| Friday 15 July | |
| Aveva Group PLC | AGM |
| DCC PLC | AGM |
| DP Poland PLC | AGM |
| Griffin Mining Ltd | AGM |
| MC Mining PLC | GM re subscription |
| Monday 18 July | |
| Audioboom Group PLC | AGM |
| JPMorgan European Discovery Trust PLC | AGM |
| Tuesday 19 July | |
| Biotech Growth Trust PLC | AGM |
| Clean Power Hydrogen PLC | AGM |
| e-Therapeutics PLC | AGM |
| Norcros PLC | AGM |
| Ten Lifestyle Group PLC | GE re commitment to sustainability, B Corp certification |
| Wednesday 20 July | |
| ADM Energy PLC | AGM |
| Alkemy Capital Investments PLC | AGM |
| DeepVerge PLC | AGM |
| easyJet PLC | GM re purchase of 56 Airbus A320neo family aircraft & conversion of 18 A320neo family aircraft |
| Fidelity China Special Situations PLC | AGM |
| HarbourVest Global Private Equity Ltd | AGM |
| HICL Infrastructure PLC | AGM |
| Novacyt SA | AGM r |
| Plaza Centers NV | AGM |
| Premier Foods PLC | AGM |
| Royal Mail PLC | AGM |
| Triad Group PLC | AGM |
| Wynnstay Properties PLC | AGM & GM re share buyback |
| Thursday 21 July | |
| Big Yellow Group PLC | AGM |
| Evgen Pharma PLC | AGM |
| Experian PLC | AGM |
| Halma PLC | AGM |
| Intermediate Capital Group PLC | AGM |
| Johnson Matthey PLC | AGM |
| Octopus AIM VCT PLC | AGM |
| Pennon Group PLC | AGM |
| Pires Investments PLC | GM re offer from Tern PLC |
| QinetiQ Group PLC | AGM |
| SSE PLC | AGM |
| Tern PLC | GM re offer for Pires Investments PLC |
| Vp PLC | AGM |
| Workspace Group PLC | AGM |
| Zephyr Energy PLC | AGM |
| Copyright 2022 Alliance News Limited. All Rights Reserved. | |
13 Jun 2022 19:22
IN BRIEF: Evgen to work with University of Michigan on asset SFX-01
Evgen Pharma PLC- Cheshire, England-based drug development company - Announces collaboration with University of Michigan, to investigate the potential anti-tumour effects of the company's lead asset SFX-01 in colorectal cancer.
Read more8 Jun 2022 14:26
Evgen Pharma starts trial to test breast cancer tablet; loss narrows
(Alliance News) - Evgen Pharma PLC on Wednesday said it would begin a trial to test a new medicinal product later this year and said its results for the most recent financial year are in line with expectations.
Read more25 May 2022 22:02
TRADING UPDATES: Tekcapital fundraise; Kromek wins US government order
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more18 Jan 2022 11:48
Evgen agrees fresh licensing deal with Spanish institutions
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced a memorandum of understanding with the University of Seville, Consejo Superior de Investigaciones Científicas (CSIC) and Fundación Pública Andaluza Progreso y Salud on behalf of the Institute of Biomedicine of Seville on Tuesday, for second-generation sulforaphane analogues.
Read more18 Jan 2022 11:32
Evgen signs agreement for Spanish institutions' sulfoaphane analogues
Evgen signs agreement for Spanish institutions' sulfoaphane analogues
Read more7 Dec 2021 21:49
EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record
EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record
Read more30 Nov 2021 16:26
UK earnings, trading statements calendar - next 7 days
UK earnings, trading statements calendar - next 7 days
Read more10 Nov 2021 18:22
TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up
TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up
Read more